While cetuximab, an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody, has been approved for the treatment of head and neck squamous cell carcinoma since 2006 (7, 8). Here, EGFR is linked to head and neck squamous cell carcinoma.